Recombinant human interleukin-2 (Ⅰ) for injection

This product shows biological activity of human natural IL-2, including increasing lymphocyte mitosis, proliferating cytotoxic T cells, natural killer cells and lymphokine-activated killer cells (LAK), and enhancing their killing activity. When the dosage of this product in the human body reaches a certain level, it will produce immune effects and induce the production of some cytokines such as tumor necrosis factor, IL-1 and gamma-interferon. This product has anti-viral, anti-tumor and immune enhancement effects.

Recombinant human interleukin-2 (125Ser)

This product can be used to treat cancerous pleural and abdominal effusions and malignant tumors such as melanoma and renal cancer.

Dissolve in sterile saline. The specific usage, dosage and course of treatment vary according to the disease. Generally, the following methods are used (or follow the doctor's advice). 1 Systemic administration: Subcutaneous injection: recombinant human interleukin-2 (125Ser) 600,000 to 1 million IU/m2 is dissolved in 2 ml of sterile saline and injected subcutaneously 3 times a week. A course of treatment is 6 weeks. 2 Regional and local administration: (1) Pleural injection: For cancerous pleural effusion, recombinant human interleukin-2 (125Ser) 1 to 2 million IU/m2 is injected after the effusion in the cavity is drained as much as possible, 1 to 2 times a week, 2 to 4 weeks (or the effusion disappears) is a course of treatment. (2)

Common adverse reactions include fever, chills, and muscle aches, which are related to the dosage. There may also be chills and high fever. Some patients may experience nausea and vomiting. A few patients may have rashes and local swelling at the injection site. All adverse reactions can be recovered after stopping the drug. When this product is used in large doses, foreign reports have shown that it may cause capillary leakage syndrome, which manifests as low blood pressure, peripheral edema, temporary renal insufficiency, etc. It should be discontinued immediately and symptomatic treatment should be actively carried out.

This product is contraindicated for patients who are allergic to its ingredients, have severe heart and kidney dysfunction, have severe hypotension, or have high fever.

This product affects the function of the central nervous system. Therefore, interactions may occur when this product is used together with psychotropic drugs (such as anesthetics, analgesics, antiemetics, sedatives, tranquilizers). If this product is co-administered with drugs that are harmful to the kidneys (such as aminoglycosides, analgesics and anti-inflammatory drugs), drugs that are toxic to the bone marrow (such as cytotoxic chemotherapy), drugs that are toxic to the heart (such as doxorubicin) or hepatotoxic drugs (such as methotrexate, asparaginase), it will enhance the toxic effects on these organ systems. The safety and efficacy of co-administering this product with any anti-tumor agent have not been confirmed. In addition, the decrease in liver and kidney function caused by the use of this product will delay the clearance of the co-administered drugs, thereby increasing these

Store at 2-8℃ away from light. The validity period is tentatively 24 months.

1 million IU/vial

Shandong Quangang Pharmaceutical Co., Ltd.

• Founded in:

  2001-04-29

• Address:

  No. 225 Jiangshuiquan Road, Jinan City

• Tax NO.:

  9137010272861438X3

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view